Search Results - "Edenfield, W. J."

Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review by Byrd, J C, Edenfield, W J, Shields, D J, Dawson, N A

“…To discuss the predisposing risk factor for all forms of extramedullary leukemia (EML) and to review the clinical features, prognostic significance, and…”
Get more information

Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes by Garcia-Manero, G, Gore, S D, Kambhampati, S, Scott, B, Tefferi, A, Cogle, C R, Edenfield, W J, Hetzer, J, Kumar, K, Laille, E, Shi, T, MacBeth, K J, Skikne, B

“…CC-486, the oral formulation of azacitidine (AZA), is an epigenetic modifier and DNA methyltransferase inhibitor in clinical development for treatment of…”
Get full text

CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome? by MURRAY, C. K, ESTEY, E, PAIETTA, E, HOWARD, R. S, EDENFIELD, W. J, PIERCE, S, MANN, K. P, BOLAN, C, BYRD, J. C

“…Blast expression of CD56 is frequent in patients with t(8;21)(q22;q22) acute myeloid leukemia and is associated with an inferior outcome. The expression of…”
Get full text

An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose by EDENFIELD, W. J, MOORES, L. K, GOODWIN, G, LEE, N

Get full text

Mechanical ventilation in hematopoietic stem cell transplantation: can We effectively predict outcomes? by Shorr, A F, Moores, L K, Edenfield, W J, Christie, R J, Fitzpatrick, T M

“…Survival rates from mechanical ventilation (MV) in allogeneic bone marrow transplantation are poor, but little is known about the need for and outcomes from MV…”
Get more information

Stage-specific application of allogeneic and autologous marrow transplantation in the management of acute myeloid leukemia by Edenfield, W J, Gore, S D

“…Allogeneic (alloBMT) and autologous bone marrow transplantation (ABMT) have become standard approaches for the management of adults with acute myeloid leukemia…”
Get more information

Recurrent Helicobacter cinaedi Bacteremia in a Patient Infected with Human Immunodeficiency Virus: Case Report by Mammen, Mammen P., Aronson, Naomi E., Edenfield, William J., Endy, Timothy P.

“…Campylobacter-like organisms, now renamed Helicobacter, have been isolated from the gastrointestinal tract and blood of patients infected with HIV. These…”
Get full text

An engraftment syndrome in autologous stem cell transplantation related to mononuclear cell dose by Edenfield, W J, Moores, L K, Goodwin, G, Lee, N

“…Engraftment syndrome (ES) is a toxicity of autologous stem cell transplantation that occurs unexpectedly and is occasionally fatal. This syndrome, manifested…”
Get full text

Extramedullary myeloid cell tumors in myelodysplastic-syndromes: not a true indication of impending acute myeloid leukemia by Byrd, J C, Edenfield, W J, Dow, N S, Aylesworth, C, Dawson, N

“…The purpose of this report is to record a patient with myelodysplastic syndrome (MDS) associated acute myelogenous leukemia (AML) and leukemia cutis who had…”
Get more information

A phase 1b study of abemaciclib, an inhibitor of CDK4 and CDK6, in combination with endocrine and HER2-targeted therapies for patients with metastatic breast cancer by Beeram, M., Tolaney, S.M., Beck, J.T., Dickler, M.N., Conlin, A.K., Dees, C., Helsten, T.L., Conkling, P.R., Edenfield, W.J., Richards, D.A., Kambhampati, S.R.P., Costigan, T.M., Chan, E., Pant, S., Kalinsky, K., Burris, H.A., Becerra, C.H., Rexer, B.N., Puhalla, S.L., Goetz, M.P.

Get full text

Randomized phase II multicenter study of the efficacy and safety of sunitinib on the 4/2 versus continuous dosing schedule as first-line therapy of metastatic renal cell carcinoma: Renal EFFECT Trial by Motzer, R. J., Hutson, T. E., Olsen, M. R., Hudes, G. R., Burke, J. M., Edenfield, W. J., Wilding, G., Martell, B., Hariharan, S., Figlin, R. A.

“…Abstract only LBA308 Background: In a randomized phase III trial, sunitinib 50 mg/d on Schedule 4/2 (4 wk on treatment [Tx], 2 wk off) showed superior…”
Get full text

A randomized phase II study comparing mFOLFOX-6 combined with axitinib or bevacizumab or both in patients with metastatic colorectal cancer (mCRC) by Infante, J. R., Cohn, A. L., Reid, T. R., Edenfield, W. J., Cescon, T., Hamm, J. T., Tarazi, J. C., Kim, S., Rosbrook, B., Cartwright, T. H.

“…Abstract only 485 Background: Vascular endothelial growth factor receptor inhibitors, including axitinib (AG-013736), may be useful in treating patients with…”
Get full text

Abstract P6-17-35: Withdrawn by Hamilton, EP, Barve, M, Bardia, A, Beeram, M, Edenfield, WJ, Noonan, A, Tolcher, A, Bendell, J, Mosher, R, Xu, J, Hailman, E, Burris III, H, Soliman, HH

“…This abstract was withdrawn by the authors. Citation Format: Hamilton EP, Barve M, Bardia A, Beeram M, Edenfield WJ, Noonan A, Tolcher A, Bendell J, Mosher R,…”
Get full text

Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer by Goetz, MP, Beeram, M, Beck, T, Conlin, AK, Dees, EC, Dickler, MN, Helsten, TL, Conkling, PR, Edenfield, WJ, Richards, DA, Turner, PK, Cai, N, Chan, EM, Pant, S, Becerra, CH, Kalinsky, K, Puhalla, SL, Rexer, BN, Burris, HA, Tolaney, SM

“…Background: Abemaciclib, a small molecule inhibitor of CDK4 and CDK6, induces G1 cell cycle arrest in Rb-proficient human cancers.1 The clinical safety profile…”
Get full text

ONGOING PHASE 1/2 STUDY OF INCB050465, A SELECTIVE PI3K[delta] INHIBITOR, FOR THE TREATMENT OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES (CITADEL-101) by Caimi, P, Ramchandren, R, Phillips, TJ, Wertheim, MS, Gutierrez, ME, Edenfield, WJ, Akard, LP, Call, JA, Persky, DO, DeMarini, DJ, Zhou, L, Yeleswaram, S, ero-Torres, A

Get full text

Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity by WASELENKO, Jamie K, BURROWS, Ann, NELSON, Douglas A, LUCAS, Margaret, EKSTRAND, John, EDENFIELD, William Jeffrey, MYHAND, Rick C

“…Given the favorable immunologic effects of IL-2 post transplant, we conducted a feasibility study examining rIL-2 1.0x106 IU/m2/day (SQ) beginning on D+14…”
Get full text